One-Year Progression-Free Survival of Therapy-Naive Patients With Malignant Pheochromocytoma and Paraganglioma
S. Hescot(Institut Curie), Anne‐Paule Gimenez‐Roqueplo(Délégation Paris 5), Jérôme Bertherat(Centre National de la Recherche Scientifique), Delphine Vezzosi(Université Toulouse III - Paul Sabatier), C. Chougnet(Université Paris-Sud), Xavier Bertagna, Claire Bournaud-Salinas, Martin Schlumberger(Université Paris-Saclay), Jean-Louis Wémeau(Université de Lille), Rossella Libé(Hôpital Cochin), Christine Do Cao(Centre Hospitalier Universitaire de Lille), Antoine Tabarin(Université de Bordeaux), Françoise Borson‐Chazot(Hospices Civils de Lyon), Isabelle Borget(Inserm), Christelle de la Fouchardière(Aix-Marseille Université), Éric Baudin(Institut Gustave Roussy), Laurence Amar(Unit of Functional and Adaptive Biology), Sophie Leboulleux(Geneva College), Patricia Niccoli(Institut Paoli-Calmettes), Jacques Young(Inserm), Pierre‐François Plouin(Hôpital Broussais), I. Raingeard(Centre Hospitalier Universitaire de Montpellier), Sophie Giraud(Hôpital Edouard Herriot)
Cited by 119
Related Papers
Management of adrenal incidentalomas: European Society of Endocrinology Clinical Practice Guideline in collaboration with the European Network for the Study of Adrenal Tumors
|European Journal of Endocrinology|2016|1.5k
Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised, open-label, phase 3 trial
|The Lancet Oncology|2021|1.3k
Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer
|Journal of Clinical Oncology|2020|1.2k
Outcomes after adrenalectomy for unilateral primary aldosteronism: an international consensus on outcome measures and analysis of remission rates in an international cohort
|The Lancet Diabetes & Endocrinology|2017|951